These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 33978269)

  • 1. Impact of renal function on residual platelet reactivity and clinical outcomes in patients with acute coronary syndrome treated with clopidogrel.
    Li Q; Chen Y; Liu Y; Yu L; Zheng J; Sun Y
    Clin Cardiol; 2021 Jun; 44(6):789-796. PubMed ID: 33978269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome.
    Ilardi F; Gargiulo G; Paolillo R; Ferrone M; Cimino S; Giugliano G; Schiattarella GG; Verde N; Stabile E; Perrino C; Cirillo P; Coscioni E; Morisco C; Esposito G
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):660-666. PubMed ID: 32520854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor.
    Verdoia M; Nardin M; Gioscia R; Suryapranata H; Kedhi E; Rognoni A; DE Luca G;
    Minerva Cardiol Angiol; 2023 Jun; 71(3):257-265. PubMed ID: 36222601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
    Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low hemoglobin predicts high-platelet reactivity and major cardiovascular ischemic events at long-term follow-up among ACS patients receiving dual antiplatelet therapy with ticagrelor.
    Verdoia M; Rolla R; Pergolini P; Gioscia R; Nardin M; Negro F; Viglione F; Suryapranata H; Kedhi E; De Luca G;
    Catheter Cardiovasc Interv; 2021 Dec; 98(7):1309-1316. PubMed ID: 33527669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.
    Barbieri L; Verdoia M; Pergolini P; Nardin M; Rolla R; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):352-8. PubMed ID: 26857781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
    Parodi G; Marcucci R; Valenti R; Gori AM; Migliorini A; Giusti B; Buonamici P; Gensini GF; Abbate R; Antoniucci D
    JAMA; 2011 Sep; 306(11):1215-23. PubMed ID: 21934054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G;
    Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Schaffer A; Barbieri L; Marino P; Bellomo G; Suryapranata H; De Luca G
    J Thromb Haemost; 2016 Jan; 14(1):57-64. PubMed ID: 26512550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Sartori C; Nardin M; Schaffer A; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Platelets; 2016 Sep; 27(6):576-82. PubMed ID: 27540959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; Luca GD;
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):143-50. PubMed ID: 26868495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Daffara V; Pergolini P; Rolla R; Marino P; Bellomo G; Carriero A; De Luca G;
    Vascul Pharmacol; 2017 Aug; 93-95():42-47. PubMed ID: 28433569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study.
    Yao Y; Li X; Wang Z; Xu S; Lv Q
    Int J Clin Pharm; 2023 Apr; 45(2):461-472. PubMed ID: 36639521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
    Verdoia M; Nardin M; Gioscia R; Negro F; Marcolongo M; Suryapranata H; Kedhi E; De Luca G;
    Vascul Pharmacol; 2020 Sep; 132():106765. PubMed ID: 32681888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation.
    Verdoia M; Sartori C; Pergolini P; Nardin M; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Feb; 77():48-53. PubMed ID: 25956733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy.
    Verdoia M; Nardin M; Sartori C; Pergolini P; Rolla R; Barbieri L; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Atherosclerosis; 2015 Dec; 243(2):389-94. PubMed ID: 26520891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.